Printer Friendly

PERSEPTIVE BIOSYSTEMS, INC. INTRODUCES FIRST REAL-TIME MONITORING DEVICE FOR BIOTECHNOLOGY PROCESSES

 CAMBRIDGE, Mass., Jan. 12 /PRNewswire/ -- PerSeptive Biosystems, Inc. (NASDAQ-NMS: PBIO) announced today that it has begun to sell its Real-Time Process Monitor(tm) (RPM)(tm), the first instrument that performs real-time immunoassays to monitor biopharmaceutical production processes such as purification and fermentation. Using RPM, biopharmaceutical developers and manufacturers can continuously track the concentration and purity of target biomolecules, including proteins, peptides and oligonucleotides or any other materials to which a binding protein can be made.
 Noubar B. Afeyan, Ph.D., president and CEO of PerSeptive, stated: "Biopharmaceutical companies currently lack the monitoring tools that are essential in efficient and consistent production processes. By providing on-line analyses, RPM has the potential of revolutionizing the development and production of biopharmaceuticals."
 Dr. Afeyan continued, "RPM also has the potential of providing consistency and quality information of importance in process validation and regulatory review. We plan to work closely with early adopters of this approach to support them in realizing this potential."
 These drugs are currently produced in processes that require multiple steps. Manufacturers must collect samples of the product after each step. Since manufacturers typically do not receive analytical laboratory results until the following day, they must either hold the process or proceed to the next step without confirmation of success in the prior step.
 The development of biopharmaceutical production processes also requires the performance of thousands of assays run on a myriad of alternative, experimental processes. Since biopharmaceutical developers lack an on-line, real-time monitoring system, they can only develop optimal purification and fermentation processes with great expense of time and money. On-line, real-time monitoring can reduce the resources spent on processes that do not result in drugs of exceptionally high purity on a consistent basis.
 Typical applications of RPM in biopharmaceutical purification processes such as chromatography and filtration include optimization of process development methods, validation of methods, assessment of batch-to-batch reproducibility and collection of fractions according to purity and concentration specifications. Typical applications in fermentation include optimization of fermentation conditions and determining the optimal time to end the fermentation.
 PerSeptive Biosystems designs, manufactures and markets proprietary products and systems for the purification and analysis of biomolecules. These bioseparations products are designed to reduce significantly the time and cost required for the development and manufacture of biopharmaceuticals. The company's current and planned products for the purification and analysis of biomolecules are based on three interrelated core technologies: Perfusion Chromatography(R), ImmunoDetection(tm) and Rational Surface Design(tm).
 ----
 NOTE: Perfusion Chromatography and POROS(R) are registered trademarks and ImmunoDetection, Rational Surface Design, and Real-Time Process Monitor are trademarks of the company.
 -0- 1/12/93
 /CONTACT: Robert A. Fein (investors), vice president and CFO, or Robert B. Anacone (industry), senior vice president, marketing and sales, 617-621-1787, both of PerSeptive Biosystems/
 (PBIO)


CO: PerSeptive Biosystems, Inc. ST: Massachusetts IN: MTC SU: PDT

CH -- NE014 -- 4160 01/12/93 15:59 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 12, 1993
Words:476
Previous Article:ALPINE CAR AUDIO PRODUCTS TO FEATURE BBE SOUND TECHNOLOGY
Next Article:OAK INDUSTRIES ACQUIRES SPECTRUM TECHNOLOGY BUSINESS
Topics:


Related Articles
PERSEPTIVE BIOSYSTEMS, INC. ANNOUNCES NEW PRESIDENT, LITIGATION AND NEW SENIOR VICE PRESIDENT
PERSEPTIVE BIOSYSTEMS, INC. INTRODUCES ID SENSOR CARTRIDGES
PERSEPTIVE BIOSYSTEMS, INC'S PROCESS DIVISION ANNOUNCES THE INTRODUCTION OF POROS 50
PERSEPTIVE BIOSYSTEMS, INC. ANNOUNCES FIRST QUARTER RESULTS
PERSEPTIVE BIOSYSTEMS AND PERSEPTIVE TECHNOLOGIES II ANNOUNCE PATENT ALLOWANCE ON DNA SEQUENCING USING MASS SPECTROMETRY
PERSEPTIVE BIOSYSTEMS NAMES SHAUN C. LONERGAN, FORMERLY OF BOEHRINGER MANNHEIM, AS SENIOR DIRECTOR, CORPORATE DEVELOPMENT
PerSeptive Biosystems, Inc. Issues 1.25 Million Common Shares to Millipore Corporation Valued at $8 Per Share
PerSeptive Biosystems Reports Results for First Fiscal Quarter of 1997
PerSeptive Biosystems Makes Major New Product Introduction At PITTCON '97
Perkin-Elmer And PerSeptive Biosystems Complete Merger

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters